Solasia Pharma K.K. announced consolidated and non-consolidated earnings results for the full year ended December 31, 2019. For the period, on consolidated basis, the company reported revenue of JPY 1,310 million against JPY 318 million a year ago. Operating loss was JPY 1,762 million against JPY 2,420 million a year ago. Loss attributable to owners of parent was JPY 1,867 million against JPY 2,422 million a year ago. Basic loss per share was JPY 17.75 against JPY 25.98 a year ago.

For the period, on non-consolidated basis, the company reported revenue of JPY 1,310 million against JPY 318 million a year ago. Operating loss was JPY 2,150 million against JPY 2,476 million a year ago. Net loss was JPY 2,204 million against JPY 2,532 million a year ago. Basic loss per share was JPY 20.96 against JPY 27.16 a year ago.

For the fiscal year ending December 31, 2020, for the period, the company expects revenue to be between JPY 500 million and JPY 2000 million, operating loss to be between JPY 2,900 million and JPY 2,000 million, Loss attributable to owners of parent to be between JPY 2,900 million and JPY 2,000 million a year ago. Basic loss per share expects to be between JPY 24.91 and JPY 17.18.